Author:
Hamy Anne-Sophie,Darrigues Lauren,Laas Enora,De Croze Diane,Topciu Lucian,Lam Giang-Thanh,Evrevin Clemence,Rozette Sonia,Laot Lucie,Lerebours Florence,Pierga Jean-Yves,Osdoit Marie,Faron Matthieu,Feron Jean-Guillaume,Laé Marick,Reyal Fabien
Funder
Site de Recherche Integrée en Cancérologie/Institut National du Cancer
Publisher
Public Library of Science (PLoS)
Reference35 articles.
1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;P. Cortazar;Lancet,2014
2. Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes;C. Hatzis;Cancer Res,2013
3. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy;W.F. Symmans;Journal of Clinical Oncology,2007
4. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL;N.M. Hylton;Radiology,2016
5. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis;M. Martín;Oncologist,2017
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献